Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03687359 · ClinicalTrials.gov registry record
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
A clinical trial of Dermatitis, Atopic, sponsored by Sanofi.
- Active
- Registry status
- 1,860
- Enrollment target
- 20
- Study locations
NCT03687359 is a study of Dermatitis, Atopic that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 1,860 participants, above the 333-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (459% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT03687359, a study of Dermatitis, Atopic, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- 1,860 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: * To characterize disease burden and unmet need. * To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching). * To document the real-world effectiveness and safety of treatments.
Conditions Studied
Interventions
- OTHER Standard of care
Study Locations (20)
Florida
- Daxia Trials- Site Number : 8400082 - Boca Raton
- Frieder Dermatology- Site Number : 8400085 - Boca Raton
- Pediatric Center of Excellence (PCE) - Miami Pediatric Endocrinology, LLC- Site Number : 8400072 - Coral Gables
- Green Dermatology and Cosmetic Center. Site Number : 8400078 - Deerfield Beach
- Amedica Research Institute, Inc.- Site Number : 8400067 - Hialeah
- Eastern Research, Inc.- Site Number : 8400032 - Hialeah
- Premier Dermatology Partners- Site Number : 8400075 - Miami
- Nicklaus Children's Hospital - Miami - Southwest 62nd Avenue- Site Number : 8400074 - Miami
- Vista Health Research, LLC- Site Number : 8400034 - Miami
- Pediatric & Adult Research Center- Site Number : 8400040 - Orlando
- Elias Dermatology LLC- Site Number : 8400086 - Pembroke Pines
- Elias Dermatology LLC- Site Number : 8400087 - Pembroke Pines
California
- Orange County Research Institute- Site Number : 8400028 - Anaheim
- Axis Clinical Trials- Site Number : 8400025 - Los Angeles
- Madera Family Medical Group- Site Number : 8400054 - Madera
- Carey Chronis, MD, FAAP- Site Number : 8400033 - Ventura
Alabama
- C Squared Research Center- Site Number : 8400068 - Birmingham
- Cahaba Dermatology & Skin Health Center- Site Number : 8400046 - Birmingham
- C2 Research Center, LLC- Site Number : 8400071 - Montgomery
Arizona
- Phoenix Children's Hospital, Inc.- Site Number : 8400015 - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,860 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2035-07-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03687359
The ClinicalTrials.gov registry entry for NCT03687359 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,860 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 333-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (459% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 1 intervention - of which Standard of care is the first listed.
NCT03687359 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT03687359 about?
NCT03687359 is a clinical study titled "Observational Evaluation of Atopic Dermatitis in Pediatric Patients". Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic c...
What is the current status of trial NCT03687359?
This trial is currently active not recruiting. The enrollment target is 1,860 participants. The study started on 2019-08-15. Estimated completion is 2035-07-23.
What conditions does trial NCT03687359 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT03687359?
The interventions under investigation include: Standard of care (OTHER).
Who is sponsoring clinical trial NCT03687359?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03687359 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.